CM
SNDX icon

Caption Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Caption Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-130,000
Closed -$2.73M – 2027
2025
Q4 		$2.73M Sell
130,000
-20,000
-13% -$349K 0.02% 722
2025
Q3 		$2.31M Sell
150,000
-621,400
-81% -$8.13M 0.02% 790
2025
Q2 		$7.22M Buy
771,400
+521,400
+209% +$5.74M 0.08% 299
2025
Q1 		$3.07M Sell
250,000
-109,300
-30% -$1.54M 0.03% 543
2024
Q4 		$4.75M Buy
359,300
+97,600
+37% +$1.67M 0.04% 385
2024
Q3 		$5.04M Buy
+261,700
New +$5.41M 0.08% 292
2024
Q1 		– Sell
-39,900
Closed -$862K – 1639
2023
Q4 		$862K Sell
39,900
-390,900
-91% -$6.01M 0.01% 839
2023
Q3 		$6.26M Buy
430,800
+400,800
+1,336% +$7.58M 0.1% 261
2023
Q2 		$628K Sell
30,000
-30,000
-50% -$625K 0.01% 771
2023
Q1 		$1.27M Buy
+60,000
New +$1.49M 0.02% 573
2020
Q4 		– Sell
-20,200
Closed -$298K – 1221
2020
Q3 		$298K Sell
20,200
-19,800
-50% -$302K 0.01% 853
2020
Q2 		$593K Buy
+40,000
New +$609K 0.02% 639

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Caption Management's SNDX Position: Q3 2025 in Review

Caption Management sold out of Syndax Pharmaceuticals (SNDX) in Q3 2025, closing a stake of 504,471 shares — an estimated $6.6M sold.

Caption Management first reported a position in SNDX in Q3 2018 and held it in 15 quarters. The position peaked at $4.72M in Q2 2025. 227 funds tracked by Wall St. Rank hold SNDX as of Q3 2025.

  • Caption Management reported no remaining Syndax Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Caption Management sold 504,471 Syndax Pharmaceuticals shares in Q3 2025, an estimated $6.6M.
  • Caption Management first reported a position in Syndax Pharmaceuticals in Q3 2018 and held it in 15 quarters.
  • Caption Management's Syndax Pharmaceuticals position peaked at $4.72M in Q2 2025.
  • 227 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2025.

Based on Caption Management's 13F filing for Q3 2025, filed 14 Nov 2025.